rgt-419b
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 4, 2022 (NCT05304962)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Cyclin-dependent kinase 2INHIBITOR
CDK2 inhibitor
- Cyclin-dependent kinase 6INHIBITOR
CDK6 inhibitor
- Cyclin-dependent kinase 4INHIBITOR
CDK4 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06299124 | Phase 1 | Apr 17, 2023 | Fudan University, Regor Pharmaceuticals Inc. |
| NCT05304962 | Phase 1 | Mar 4, 2022 | Regor Pharmaceuticals Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Regor Pharmaceuticals Inc. | For profit | 2 | 2 | 1 | 2022 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1